The rapid expansion of glucagon-like peptide-1 (GLP-1) receptor agonist prescribing to children and adolescents represents one of the most consequential developments in recent pediatric practice. These agents, such as semaglutide (Wegovy), tirzepatide (Zepbound/Mounjaro), and liraglutide (Saxenda), have demonstrated efficacy in weight reduction in adult populations. Their application to pediatric patients, however, raises concerns that warrant careful examination: the adequacy of the safety evidence, the influence of commercial interests on clinical guidance, and the failure to address the root causes of childhood obesity.

This analysis reviews the available evidence, with particular attention to a recent case that illustrates the potential consequences of expanding these agents into younger populations.

The Case of Josephine Nasr

On September 23, 2025, a 19-year-old university student, Josephine Nasr, was found deceased in her dormitory in London. According to testimony presented at the East London Coroner’s Court, Nasr, described by the attending pathologist as “an otherwise healthy young woman,” had been prescribed tirzepatide by a California physician in the summer of 2025, despite a body mass index that classified her as overweight rather than obese.

On the evening of her death, Nasr reported nausea and vomiting to her family. Her sister, concerned about dehydration, arranged for intravenous fluids through a private healthcare provider. The fluids arrived too late.

Post-mortem examination identified a congenital condition known as myocardial bridging which is a common anatomical variant in which a segment of coronary artery courses through the myocardium. The pathologist testified that tirzepatide-induced vomiting can produce hypoglycemia and electrolyte imbalance, which may precipitate fatal arrhythmia in a susceptible individual. The coroner concluded that death was attributable to both the congenital cardiac variant and the tirzepatide prescription.

This case merits attention not because it is typical, but because it illustrates the mechanism by which these agents can produce serious harm and the absence of safeguards that might have prevented it.

The AAP Guideline: Timing and Financial Conflicts

In January 2023, the American Academy of Pediatrics (AAP) published its Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. The guideline recommended pharmacotherapy for children as young as 8 years (off-label) and evaluation for bariatric surgery in adolescents as young as 13.

The timing was notable: the guideline followed within weeks of FDA expansion of GLP-1 approval to adolescents.

In July 2025, the British Medical Journal published an investigation identifying financial relationships between the AAP and manufacturers of GLP-1 agents that were not disclosed in the guideline documents. The findings included:

• Approximately $2 million in corporate sponsorship from 11 GLP-1 drug developers to the AAP between 2012 and 2024: a figure the investigators characterized as conservative
• Personal payments to 37% of the guideline-writing committee (10 of 27 members), totaling $74,205 between 2017 and 2023
• Payments to 22% of the AAP’s national leadership (17 of 77 members), totaling $293,400 during the same period
• No disclosure of these relationships in either the guidelines or the accompanying technical report

The BMJ further noted that comparable pediatric bodies in the United Kingdom, Sweden, and Australia recommend against weight-loss pharmacotherapy in children under 12. The AAP’s position is an outlier among peer institutions.

Prescribing Trends Following the Guideline

The increase in pediatric prescribing following the AAP guideline was substantial:

• A 38% increase in GLP-1 prescriptions for pediatric patients in the first year
• A 700% increase for two specific agents, as reported by MedPage Today
• CDC data indicating an approximately 300% increase in obesity-medication prescribing among adolescents from 2020 to 2023
• Semaglutide now comprising 57% of adolescent obesity prescriptions, with 83% of prescriptions directed to patients with severe obesity

The CDC’s framing that only 0.5% of adolescents with obesity received such prescriptions in 2023 obscures the trajectory. The key observation is the rate of change: a 300% increase within a single year, concentrated in the most vulnerable patients, immediately following the publication of a guideline with undisclosed industry ties.

Cardiac Effects: Direct and Indirect Mechanisms

GLP-1 receptors are widely distributed throughout the body, including the heart. A 2024 study published in Cardiovascular Research demonstrated that GLP-1 binds receptors in the sinoatrial node (the heart’s pacemaker) producing a direct chronotropic effect independent of autonomic innervation. The clinical trials of these agents consistently document small but measurable increases in heart rate.

The cardiac risk is compounded by a second, indirect mechanism. The gastrointestinal effects of these agents including nausea, vomiting, and diarrhea can produce dehydration and electrolyte depletion. A 2025 case report described a 57-year-old patient without prior cardiac history who developed ventricular fibrillation and cardiac arrest secondary to tirzepatide-induced vomiting and resultant hypokalemia and hypomagnesemia. Coronary angiography was unremarkable. The authors characterized this as a previously undocumented risk.

The relevance to pediatric prescribing is direct: the Mounjaro pediatric label itself reports a higher incidence of vomiting and abdominal pain in children than in adults. The adverse effect most implicated in the Nasr case is more common in the very population now being targeted.

Gastrointestinal Effects: Delayed Gastric Emptying

The mechanism by which GLP-1 agents produce weight loss includes delayed gastric emptying defined by a reduction in antral and duodenal motility with increased pyloric tone. In a subset of patients, this effect progresses to clinically significant gastroparesis.

The available data indicate:

• Approximately 19% of patients treated with GLP-1 agents develop delayed gastric emptying
• Semaglutide carries a 3.3-fold higher risk of gastroparesis relative to other weight-loss agents, and a 6.1-fold higher risk relative to bariatric surgery
• The FDA added ileus and intestinal obstruction to the Ozempic label in September 2023
• A 2026 study found that 49% of fasted patients on semaglutide retained a full stomach on preoperative ultrasound, compared with 18% of controls

In pediatric patients, whose gastrointestinal physiology differs from adults, the long-term consequences of chronic pharmacologic suppression of gastric motility are unknown.

Body Composition: Lean Mass Loss

Of the total weight lost with semaglutide, approximately 45% is lean mass (muscle and bone) rather than adipose tissue. In the STEP-1 trial, semaglutide-treated patients lost 15.3 kg total, of which 6.92 kg was lean mass. Tirzepatide is associated with a lower proportion (approximately 25%), though the absolute lean mass loss remains substantial at higher doses.

For adult patients, this is a recognized concern. For pediatric patients, it is more serious. Childhood and adolescence represent the window for the building of peak bone density and muscle mass. Pharmacologically induced loss of lean tissue during this period may produce deficits that cannot be recovered in adulthood. Furthermore, the loss of metabolically active tissue contributes to the weight regain observed upon discontinuation.  This is a factor that renders these agents, in practice, a long-term or indefinite therapy rather than a discrete treatment course.

The Question of Mechanism Across Organ Systems

The distribution of GLP-1 receptors in the brain, gut, pancreas, heart, kidneys, lungs, thyroid, vasculature, adipose tissue, immune cells, and bone raises a question that the current evidence cannot answer: what function do these receptors serve in organs unrelated to appetite regulation, and what are the consequences of chronic pharmacologic activation during development?

The emerging literature on GLP-1 agents in neurodegenerative disease including Parkinson’s disease, demonstrates that these receptors mediate effects far beyond glycemic control. The mechanisms are incompletely understood. This is not an argument against investigating therapeutic applications; it is an argument against extrapolating short-term adult safety data to pediatric populations on the assumption that uncharacterized receptor functions are irrelevant.

The pediatric approval of Mounjaro for type 2 diabetes rests on a 30-week trial involving 99 pediatric patients. The longest pediatric weight-loss trial spanned 68 weeks. Neither provides data on growth, pubertal development, bone density, neurodevelopment, or fertility over the decades a child would be expected to remain on treatment.

Conclusion

The expansion of GLP-1 receptor agonists into pediatric practice has outpaced the evidence. The guideline that accelerated this expansion was authored by individuals with undisclosed financial relationships to the manufacturers. The safety data in pediatric populations are of insufficient duration to characterize long-term risk. The known adverse effects discussed above such as gastroparesis, electrolyte disturbance, cardiac chronotropy, and lean mass loss are more consequential in a developing child than in an adult.

Underlying this is a more fundamental question. Childhood obesity is a symptom of an altered food environment: ultra-processed foods, GMOs and their associated pesticides, refined carbohydrates, seed oils, endocrine-disrupting chemicals, and a sedentary, screen-based childhood. Pharmacologic appetite suppression addresses none of these. It intervenes downstream of the pathology while leaving the causes intact.

A therapeutic approach that treats the symptom while ignoring the etiology and that commits a child to indefinite medication without long-term safety data does not meet the standard of care to which pediatric patients are entitled.